Sulfamoxole

Sensitivity to sulfonamides, severe renal or hepatic impairment, porphyria, SLE; infants <2 mth; pregnancy (3rd trimester), lactation.

Renal insufficiency, elderly, blood dyscrasias, G6PD deficiency, AIDS.

Nausea, vomitting, diarrhoea, hypersensitivity skin reaction, hypothyroidism, crystalluria, renal impairment , blood dyscrasias, kernicterus in premature neonates.
Potentially Fatal: Stevens-Johnson syndrome, agranulocytosis and aplastic anaemia.

Concurrent use may increase phenytoin and methotrexate levels; increased risk of bleeding with warfarin and acenocoumarol; may potentiates antidiabetic effect of sulfonylureas.
Potentially Fatal: Increased risk of blood dyscrasias with clozapine and pyrimethamine.

Interference with tests for urea, creatinine, urinary glucose, urobilinogen.

Description:
Mechanism of Action: Sulfamoxole interferes with nucleic acid synthesis in microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid.

Sulphonamid